tabac-GO: Pregnant Women's Knowledge of the Active and Passive Smoking Effects on Pregnancy and the Fetus

Sponsor
Université de Reims Champagne-Ardenne (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT06117943
Collaborator
(none)
500
2
5
250
50.1

Study Details

Study Description

Brief Summary

There are two remaining areas where the standards for tobacco use during pregnancy have changed little: one area is the high level of consumption by pregnant women and the other is the limited care given to pregnant women.

Indeed, many pregnant women are still over-exposed to tobacco, either through personal use or passive exposure to cigarette smoke. This passive exposure often comes from the consumption of their loved ones, such as their future co-parent or family.

However, throughout our lives, health professionals, associations, and the government send a lot of information and messages about the negative effects of tobacco on health, pregnancy, and the fetus.

This information and the possibility of receiving help from a professional trained in tobacco use exist throughout the entire pregnancy.

However, many women and their partners still do not take the necessary precautions to reduce or stop smoking. Do couples who smoke during pregnancy really have an understanding of the smoking's effects on women and their fetuses? Could they realize it and would they reduce or stop their consumption, in case they knew these negative effects?

Condition or Disease Intervention/Treatment Phase
  • Other: data collection

Detailed Description

The aims are:
  • To describe the knowledge of pregnant women who smoke or are exposed to tobacco smoke about the effects of active and passive smoking on the obstetrical and fetal systems.

  • To identify the information that has been received by pregnant women who smoke or are confronted with tobacco smoke about the effects of tobacco on pregnancy.

  • To identify information sources for pregnant women who smoke or are exposed to tobacco smoke about the negative effects of tobacco on pregnancy.

Study Design

Study Type:
Observational
Anticipated Enrollment :
500 participants
Observational Model:
Case-Only
Time Perspective:
Cross-Sectional
Official Title:
Pregnant Women's Knowledge of the Active and Passive Smoking Effects on Pregnancy and the Fetus
Anticipated Study Start Date :
Dec 1, 2023
Anticipated Primary Completion Date :
Feb 1, 2024
Anticipated Study Completion Date :
May 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Pregnant women

Pregnant women who smoke personally or are passively exposed to cigarette smoke

Other: data collection
Pregnant women who smoke personally or are passively exposed to cigarette smoke

Outcome Measures

Primary Outcome Measures

  1. smoking effects on pregnancy questionnaire [day0]

    Pregnant women's knowledge of the active and passive smoking effects on pregnancy : does the woman know or not risk of miscarriage, ectopic pregnancy, premature birth, premature rupture of membranes, low-lying placenta and retro-placental hematoma associated with smoking

  2. smoking effects on the fetus questionnaire [day0]

    Pregnant women's knowledge of the active and passive smoking effects on the fetus : does the woman know or not risk of premature birth, growth delay, malformation, sudden infant death syndrome associated with smoking

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • pregnant women after 32 weeks of amenorrhea

  • Primigravida women

  • women exposed to passive or active smoking

  • women aged over 18 years

  • Accepting to participate in the study

Exclusion Criteria:
  • Minors

  • protected by law (guardianship, custodianship, judicial protection)

  • refusing to participate in the study

Contacts and Locations

Locations

Site City State Country Postal Code
1 Ufr Medecine Urca Reims France 51100
2 Université de Reims Champagne Ardenne Reims France 51100

Sponsors and Collaborators

  • Université de Reims Champagne-Ardenne

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Université de Reims Champagne-Ardenne
ClinicalTrials.gov Identifier:
NCT06117943
Other Study ID Numbers:
  • 2023_RIPH_013_tabac-GO
First Posted:
Nov 7, 2023
Last Update Posted:
Nov 7, 2023
Last Verified:
Oct 1, 2023
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Université de Reims Champagne-Ardenne

Study Results

No Results Posted as of Nov 7, 2023